Latest News
From GLP-1 Trial Results to the Follow-Up Visit
A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...
Latest News
Biotech IPO Tracker 2026: How This Year’s Listings Have Traded
Biotech IPO tracker last updated: 10 November 2026. Prices as of the 6 November 2026 close. After a lean 2025, this year has reopened the US market for biotech flotations. This biotech IPO tracker lists every US-listed drug developer that has priced an initial public...
Creative Biolabs Helps Improve Reproducibility Across iPSC Organoid Studies
As iPSC-derived organoids gain importance in disease modeling and drug discovery, Creative Biolabs highlights iPSC differentiation consistency, cell characterization, and application-specific validation to help researchers develop more reliable experimental models....
Factor XIa Inhibitor Approved: How Asundexian Compares With Milvexian
The first factor XIa inhibitor approved in the US is Bayer’s asundexian, sold as Sunharbo. It cannot yet be compared directly with milvexian, the rival from Bristol Myers Squibb and Johnson & Johnson. No head-to-head trial exists, and milvexian’s stroke results...
Longevity Science Is Advancing. Can Clinical Care Keep Up?
The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Three Grant Budget Rules That Quietly Cost Life Science SMEs Money
Most biotech and medtech teams that lose grant money do not lose it by being ineligible. They lose it by putting a correct cost in the wrong line. The three grant budget rules below come up in almost every budget review: one from Horizon Europe, one from US federal...
GLP-1 Medications List: Every Approved GLP-1 Receptor Agonist Compared (2026)
Regulatory status checked on 11 November 2026. Seven molecules make up the approved GLP-1 class in the US, Europe and the UK. They differ in dosing, in whether they are injections or tablets, and in the conditions they treat. This GLP-1 medications list covers every...
What It Takes To Move Biomanufacturing Toward Commercial Scale
Scientific breakthroughs get attention for good reason. They are the moments when something that did not exist before suddenly becomes possible. But anyone who has spent time trying to commercialize biotechnology learns another lesson pretty quickly: proving that...
GLP-1 Vision Loss: What Does the FDA’s New NAION Warning Mean?
The FDA now requires every GLP-1 receptor agonist label to carry a warning about a rare eye condition. The condition is non-arteritic anterior ischaemic optic neuropathy, or NAION. The agency announced the change in a drug safety communication on 9 November 2026. For...
ANI Egetis Offer: What Is ANI Paying and When Could It Close?
ANI Pharmaceuticals is offering SEK 11.25 in cash for each share in Egetis Therapeutics. ANI puts the total value of the ANI Egetis offer at about SEK 5.6 billion, or about $560 million. The offer was announced on 5 November 2026 and has not completed. The acceptance...
The Healthcare AI That Wins Won’t Be the One With the Best Demo
Healthcare has no shortage of impressive AI demos. Scaling healthcare AI is another matter. A model can summarize a chart in seconds. An ambient tool can generate a clinical note from a conversation. An AI agent can identify a denied claim or suggest the next...
Lilly vs Novo in 2026: How the Obesity Market Has Shifted
Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...
Povetacicept FDA Decision: Will Vertex Win Approval by 30 November?
The povetacicept FDA decision is due by 30 November 2026. The evidence points towards a plausible approval but does not settle it. Vertex Pharmaceuticals says its application for accelerated approval in IgA nephropathy (IgAN) is under priority review. The company’s...
The Signature Is the Safeguard: Where AI Belongs in Mental Health Care
Most of the argument about AI in mental health care is about chatbots that talk like therapists. The bigger change is happening somewhere less visible: in the notes, forms and insurance paperwork that sit between a clinician and the next person they are trying to...
Why Medical Electronics Are the Hardest E-Waste to Recycle
Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...
Weekly News Roundup | 9 November 2026
Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...
Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?
Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...
Three Grant Budget Rules That Quietly Cost Life Science SMEs Money
Most biotech and medtech teams that lose grant money do not lose it by being ineligible. They lose it by putting a correct cost in the wrong line. The three grant budget rules below come up in almost every budget review: one from Horizon Europe, one from US federal...
GLP-1 Medications List: Every Approved GLP-1 Receptor Agonist Compared (2026)
Regulatory status checked on 11 November 2026. Seven molecules make up the approved GLP-1 class in the US, Europe and the UK. They differ in dosing, in whether they are injections or tablets, and in the conditions they treat. This GLP-1 medications list covers every...
What It Takes To Move Biomanufacturing Toward Commercial Scale
Scientific breakthroughs get attention for good reason. They are the moments when something that did not exist before suddenly becomes possible. But anyone who has spent time trying to commercialize biotechnology learns another lesson pretty quickly: proving that...
GLP-1 Vision Loss: What Does the FDA’s New NAION Warning Mean?
The FDA now requires every GLP-1 receptor agonist label to carry a warning about a rare eye condition. The condition is non-arteritic anterior ischaemic optic neuropathy, or NAION. The agency announced the change in a drug safety communication on 9 November 2026. For...
ANI Egetis Offer: What Is ANI Paying and When Could It Close?
ANI Pharmaceuticals is offering SEK 11.25 in cash for each share in Egetis Therapeutics. ANI puts the total value of the ANI Egetis offer at about SEK 5.6 billion, or about $560 million. The offer was announced on 5 November 2026 and has not completed. The acceptance...
The Healthcare AI That Wins Won’t Be the One With the Best Demo
Healthcare has no shortage of impressive AI demos. Scaling healthcare AI is another matter. A model can summarize a chart in seconds. An ambient tool can generate a clinical note from a conversation. An AI agent can identify a denied claim or suggest the next...
Lilly vs Novo in 2026: How the Obesity Market Has Shifted
Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...
Povetacicept FDA Decision: Will Vertex Win Approval by 30 November?
The povetacicept FDA decision is due by 30 November 2026. The evidence points towards a plausible approval but does not settle it. Vertex Pharmaceuticals says its application for accelerated approval in IgA nephropathy (IgAN) is under priority review. The company’s...
The Signature Is the Safeguard: Where AI Belongs in Mental Health Care
Most of the argument about AI in mental health care is about chatbots that talk like therapists. The bigger change is happening somewhere less visible: in the notes, forms and insurance paperwork that sit between a clinician and the next person they are trying to...
Why Medical Electronics Are the Hardest E-Waste to Recycle
Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...
Weekly News Roundup | 9 November 2026
Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...
Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?
Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...
Featured Articles
Further News
What Happened When We Gave Business Classes Our Real Production Data
At Karviva, we used several Google Sheets to keep track of ingredients, materials, production and orders. As the business grew, keeping those records connected became harder. We needed to plan production more reliably and trace each batch from its ingredients through...
Clinical Trial Results 6 November 2026
The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...
AI in Drug Discovery Is Great. Don’t Forget About AI in Drug Development
Artificial intelligence and the buzz around it feel like they're moving at warp speed. As this acceleration continues, especially in the life sciences, we need to pause and understand the vast differences between two uses of artificial intelligence that couldn’t be...
MariTide Approval: When Could Amgen’s Obesity Drug Reach Patients?
MariTide approval cannot be decided until Amgen files, and a search on 5 November 2026 found no filing announcement. BioSpace reported on 4 November 2026 that the first Phase 3 data are expected in 2027. The same report gave no regulatory filing timeline. Amgen’s...
In Vivo CAR-T Is Shifting the Engineering Challenge Into Delivery
CAR T-cell therapy is revolutionizing cancer treatment and being applied to a variety of other indications, but the approach relies on engineering a patient’s immune cells to recognize and attack cancer. Producing those cells can involve a complex, resource- and...
AbbVie Nxera Deal: What Does AbbVie Get for $100 Million Upfront?
The AbbVie Nxera deal gives AbbVie exclusive worldwide rights to develop and commercialise NXE0033744 in inflammatory bowel disease (IBD). The price is $100 million upfront, plus up to $1.37 billion in milestones and tiered royalties. Nxera Pharma announced the...
Hygiene Poverty and the Overlooked Toileting Needs of Women
If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....
Pharma Q3 2026 Earnings: GLP-1s, the Keytruda Cliff and Vaccines
Eli Lilly began 2026 expecting revenue of $80bn to $83bn. After its third quarter, it now expects $91bn to $92bn. Lilly’s sales reached $24.4bn in the three months to September, up 39%. Most of its large peers grew in single digits. Read together, pharma Q3 2026...
Preservative-Free Is Not Risk-Free: The Microbiology Behind Safe Cosmetics
I have noticed that many shoppers want cosmetics without preservatives, so brands have launched preservative-free cosmetics and other “free-from” lines. The science of microbiology however stays the same. Any product that holds water and nutrients can feed microbes....
COMP360 Approval: When Could Compass’s Psilocybin Be Cleared?
No COMP360 approval date exists yet, but the timetable is short. Compass Pathways said its rolling new drug application (NDA) should finish “in the next two weeks”. It made the statement on 3 November 2026, in its third-quarter 2026 results release. The company...
What Happens After a Digital Mental Health Screening Result
A self-assessment can identify symptoms, but the value of mental health screening depends on what people understand, choose and can access after seeing the result. A person completes an online mental health questionnaire and receives a score suggesting that...
Rethinking Biologics Plants to Earn Attractive Returns
The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.